The effect of omega-3 on drug resistant epilepsy
Phase 2
- Conditions
- epilepsy.Nonspecific epileptic seizures:•atonic
- Registration Number
- IRCT2015062922142N2
- Lead Sponsor
- hamadan university of medical sciences, Vice-chancellor for research and technology , Hamedan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
drug resistant epilepsy; 18 to 65 years old.
Exclusion criteria: patients with impaired renal function; patients with catamenial seizure; Patients with hepatic dysfunction; Patients with active infection; Patients with brain or mental dysfunction; Patients who can not take oral medication; Patients treated with anti-inflammatory or antioxidant drugs in the past month; patients with other concurrent inflammatory disease; Patients who can not tolerate the side effects; Patients who are pregnant or lactating
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The frequency of attacks. Timepoint: Up to 4 months after the start treatment. Method of measurement: Quantitatively.
- Secondary Outcome Measures
Name Time Method IL-6. Timepoint: Before the intervention-4 months after the treatment. Method of measurement: pg per ml by ELISA.;TNF-a. Timepoint: Before the intervention-4 months after the treatment. Method of measurement: pg per ml by ELISA.